Treatment of stress urinary incontinence with adipose tissue-derived stem cells

Lin, Guiting; Wang, Guifang; Banie, Lia; Ning, Hongxiu; Shindel, A.W.; Fandel, Thomas M.; Lue, Tom F.; Lin, Ching Shwun

doi:10.3109/14653240903350265

Cited by 183 publications

(177 citation statements)

References 33 publications

Supporting

Mentioning

171

Contrasting

Unclassified

Order By: Relevance

“…In 2010, we found that transplantation of ADSCs via urethral or intravenous injection was effective in the treatment or prevention of SUI in a vaginal balloon dilation model [73]. Activation of VEGF and ERK1/2 signaling pathway might be responsible for the paracrine effects of ADSCs in this model [74].…”

Section: Stress Urinary Incontinence (Sui)mentioning

confidence: 99%

Potential application of adipose tissue-derived stem cells for urological Disease

Lin

Lue

2014

Bladder

Self Cite

View full text Add to dashboard Cite

Adipose tissue-derived stem cells (ADSCs) are a somatic stem cell population contained in fat tissue that may be utilized in the treatment of urologic disease. ADSCs are excellent candidates for these therapies as they are easily obtained in large quantities from adipose tissue, and possess the potential to undergo long-term proliferation, self-renewal and multipotent differentiation. We reviewed the available evidence from 1964 through 2014 concerning ADSC availability, differentiation, and potentiality in the context of treatment for urologic diseases.

show abstract

Section: Stress Urinary Incontinence (Sui)mentioning

confidence: 99%

Potential application of adipose tissue-derived stem cells for urological Disease

Lin

Lue

2014

Bladder

Self Cite

View full text Add to dashboard Cite

show abstract

“…To date, treatment avenues for voiding dysfunction and urinary incontinence have focused on this potential to restore function via differentiation to replace injured or diseased tissues such as smooth or striated muscle for urethral sphincter regeneration and urothelial tissue for bladder, urethral, and upper urinary tract reconstruction [Al-Awqati and Oliver, 2002;Chermansky et al 2004b;Cruz et al 2011]. It is thought that MSCs restore function in SUI primarily by their ability to differentiate into multiple cell lineages, with animal studies demonstrating increases in urethral muscle, nerves, and connective tissue following MSC injection [Chermansky et al 2004b;Fu et al 2010;Kim et al 2010;Lin et al 2010]. MSCs have also been induced to differentiate into a smooth muscle phenotype when exposed to conditioned media from smooth muscle cell cultures or when induced with specific myogenic growth factors for application to bladder reconstruction .…”

Section: Stem Cell Differentiationmentioning

confidence: 99%

“…Stem cells may also exert a therapeutic effect via the secretion of bioactive factors that have antiapoptotic, antiscarring, neovascularization, and immunomodulatory effects on innate tissues and can direct innate stem and progenitor cells to the area of injury [Gnecchi et al 2008]. Multiple treatment avenues using stem cells for voiding dysfunction, especially SUI, have been evaluated with preclinical animal models and clinical trials demonstrating their potential to restore function via direct effects on the underlying mechanisms that lead to incontinence or voiding dysfunction [Chermansky et al 2004a;Carr et al 2008;Fu et al 2010;Huang et al 2010;Kim et al 2010;Lim et al 2010;Lin et al 2010;Cruz et al 2011;Woo et al 2011;Lee et al 2012;Carr et al 2013;Dissaranan et al 2013;Gotoh et al 2013;Rovner, 2013]. Nonetheless, many challenges remain to translate these promising results to clinical practice.…”

Section: Introductionmentioning

confidence: 99%

The potential role of stem cells in the treatment of urinary incontinence

Tran

Damaser

2014

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Voiding dysfunction encompasses a wide range of urologic disorders including stress urinary incontinence and overactive bladder that have a detrimental impact on the quality of life of millions of men and women worldwide. In recent years, we have greatly expanded our understanding of the pathophysiology of these clinical conditions. However, current gold standard therapies often provide symptomatic relief without targeting the underlying etiology of disease development. Recently, the use of stem cells to halt disease progression and reverse underlying pathology has emerged as a promising method to restore normal voiding function. Stem cells are classically thought to aid in tissue repair via their ability for multilineage differentiation and self-renewal. They may also exert a therapeutic effect via the secretion of bioactive factors that direct other stem and progenitor cells to the area of injury, and that also possess antiapoptotic, antiscarring, neovascularization, and immunomodulatory properties. Local injections of mesenchymal, muscle-derived, and adipose-derived stem cells have all yielded successful outcomes in animal models of mechanical, nerve, or external urethral sphincter injury in stress urinary incontinence. Similarly, direct injection of mesenchymal and adipose-derived stem cells into the bladder in animal models of bladder overactivity have demonstrated efficacy. Early clinical trials using stem cells for the treatment of stress urinary incontinence in both male and female patients have also achieved promising functional results with minimal adverse effects. Although many challenges remain to be addressed prior to the clinical implementation of this technology, novel stem-cell-based therapies are an exciting potential therapy for voiding dysfunction.

show abstract

“…This is relevant for patients with bladder malignancies who require bladder augmentation or replacement but do not have enough normal, non-malignant bladder cells to use in tissue engineering applications. Other MSC such as skeletal muscle-derived progenitor cells 79-88 89-92 and adipose stem cells 80,90,91,[93][94][95][96][97][98] have been investigated as potential candidates for cell-based tissue engineering and injection therapy stress urinary incontinence (SUI), and these studies are further described in Section 5.…”

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%